Recommended Chemotherapy for Gastric Neuroendocrine Carcinoma
For poorly differentiated gastric neuroendocrine carcinoma (NEC), platinum-based chemotherapy with either cisplatin plus etoposide or cisplatin plus irinotecan is the recommended first-line treatment, following the same approach as small cell lung cancer. 1
Treatment Algorithm Based on Tumor Grade
High-Grade/Poorly Differentiated Gastric NEC
The NCCN guidelines explicitly direct treatment of poorly differentiated (high-grade or anaplastic) or small cell subtype neuroendocrine tumors from sites other than lung to follow the Small Cell Lung Cancer guidelines 1. This translates to:
Preferred First-Line Regimens:
Cisplatin plus irinotecan - This combination has demonstrated a 75% response rate in gastric NEC patients, with median progression-free survival of 212 days and median overall survival of 679 days 2. This regimen is particularly effective for gastric poorly-differentiated neuroendocrine carcinoma 2, 3.
Cisplatin plus etoposide - The established standard platinum-doublet regimen for advanced gastroenteropancreatic NEC 4, 5, 6. Meta-analysis shows an overall response rate of 44.4% with median OS of 12.9 months and median PFS of 5.4 months 4.
Alternative Regimens:
- Carboplatin plus etoposide - Can substitute for cisplatin in patients unable to tolerate cisplatin 5, 6
- Carboplatin plus irinotecan - Alternative platinum-irinotecan combination 4
Key Prognostic Factors Affecting Treatment Selection
Ki-67 proliferation index is critical for treatment decisions:
- Patients with Ki-67 ≤55% have significantly better outcomes: median PFS of 19.3 months versus 6.3 months for Ki-67 >55% (p<0.01), and median OS not reached versus 8.1 months (p=0.039) 6
- For Ki-67 >55%, expect more aggressive disease with limited chemotherapy response 5, 6
Tumor differentiation matters:
- Well-differentiated NET G3 (which can occur in gastric location) shows limited response to platinum-based chemotherapy and may benefit from temozolomide-based regimens or peptide receptor radiotherapy instead 5
- Poorly differentiated NEC requires platinum-based chemotherapy as outlined above 1, 5
Well-Differentiated Gastric NETs (G1-G2)
For moderate and well-differentiated neuroendocrine tumors, the NCCN guidelines direct treatment according to the Neuroendocrine Tumors for Carcinoid Tumors guidelines 1. These typically do not require cytotoxic chemotherapy as first-line treatment and are managed with somatostatin analogues, targeted therapies, or peptide receptor radionuclide therapy 7.
Important Clinical Caveats
Performance status requirements: Chemotherapy should be considered in symptomatic patients with performance status 1-2 or asymptomatic patients (PS 0) with aggressive cancer 1.
Response monitoring: The platinum-irinotecan combination (cisplatin plus CPT-11) has shown ability to achieve partial responses allowing for subsequent surgical resection in initially unresectable cases 3.
Second-line options: No established standard exists for second-line treatment after platinum-based chemotherapy failure in gastric NEC 5. Clinical trial enrollment should be strongly considered.
Body mass index consideration: Patients with BMI <25 demonstrate better prognosis with platinum-based chemotherapy (mOS 11.7 months for BMI ≥25 versus not reached for BMI <25, p=0.0293) 6.